Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.

ABSTRACT: Ovarian cancer accounts for most deaths from gynecologic malignancies. Although more than 80% of patients respond to first-line standard of care, most of these responders present with recurrence and eventually succumb to carcinomatosis and chemotherapy-resistant disease. To improve patient survival, new modalities must, therefore, target or prevent recurrent disease. Here we describe for the first time a novel syngeneic mouse model of recurrent high-grade serous ovarian cancer (HGSOC), which allows immunotherapeutic interventions in a time course relevant to human carcinomatosis and disease course. Using this model, we demonstrate the efficacy of Transimmunization (TI), a dendritic cell (DC) vaccination strategy that uses autologous and physiologically derived DC loaded with autologous who

SUBMITTER: Alvero AB 

PROVIDER: S-EPMC7302442 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature